2025 Q4 -tulosraportti
57 päivää sitten
‧47 min
4,00 SEK/osake
Irtoamispäivä 8.5.
1,55%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 57 | - | - | ||
| 43 | - | - | ||
| 10 | - | - | ||
| 40 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 8.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten · MuokattuRaySearch is, in my opinion, an extremely interesting company in medical technology right now. For many years, the company has built up a strong position in advanced software for radiation therapy, where their systems are used by hospitals worldwide to plan and optimize cancer treatments. What makes the case particularly exciting is the combination of a high technological level, strong market position, and a structurally growth-driven market. The demand for more advanced and individualized radiation therapy continues to increase globally, and RaySearch is well positioned with its software platform, which is being integrated into an increasing number of clinics. AI is sometimes highlighted as a potential threat to software companies in medical technology, but in RaySearch's case, the development can rather become a strengthening of their offering. Radiation therapy requires complex planning, large amounts of clinical data, and deep integration into hospital systems. Here, RaySearch has already built up a comprehensive platform and long experience in the field, which means that AI is likely to become a tool that improves and automates parts of the process rather than something that replaces the company's solutions. As more hospitals digitize their treatment workflows and at the same time begin to integrate more advanced analysis and automation, RaySearch can therefore gain an even more important role in the infrastructure surrounding modern cancer treatment. What do you think?
·30.3.P/E for the current year is expected to land at 21 according to market data. The reports are better than expected. No threats from competitors, instead Philips is shutting down in 2027, so free market shares are available to take. Board members are buying heavily. The company continues to grow well and AI is no threat in the near term. Why isn't the share price rising when it has been halved? Well, it's probably the short sellers who are slandering the company just like they do with Bonex. The Financial Supervisory Authority seems to be sleeping its Sleeping Beauty sleep instead of locking up crooks who earn millions from stock manipulation through defamation. The market is out of play again. Nothing is happening...
·24.2.I don't understand how software will be outcompeted by AI… to me, it sounds like saying that a chef DOES NOT need their kitchen and their ingredients to be able to cook food. Does anyone agree with me?
·5.3.They have used machine learning for the last ten years, nowadays AI
·16.2.PE 27 at an all-time low. EBIT at an all-time high. Dividend raised by 33% Record revenue. I find it hard to see AI as a threat. Who takes medical responsibility for malpractice?
·18.2.Bought this stock at the same price level as now in 2007 and sold the last ones in 2015 for approx. 75 kr. Felt good then after having bounced at 10 kr when the financial crisis characterized life on the stock market. Now ended up back on the radar via a thread about another medtech company (Dynavox). Time to delve into Raysearch anno 2026 and going forward. Find it extremely difficult to see that AI should be a threat, rather the opposite. There are reports showing that Swedish radiation therapy has fallen behind our Nordic neighbours. One of the reasons is that there is a shortage of oncologists in radiation. AI can relieve these so that the quality of care can be maintained. Relieve, therefore, not replace. It is a low cost in this context to invest in a technology that frees up personnel resources. So as for AI, I am not worried. Other parts I will try to delve into.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
57 päivää sitten
‧47 min
4,00 SEK/osake
Irtoamispäivä 8.5.
1,55%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuRaySearch is, in my opinion, an extremely interesting company in medical technology right now. For many years, the company has built up a strong position in advanced software for radiation therapy, where their systems are used by hospitals worldwide to plan and optimize cancer treatments. What makes the case particularly exciting is the combination of a high technological level, strong market position, and a structurally growth-driven market. The demand for more advanced and individualized radiation therapy continues to increase globally, and RaySearch is well positioned with its software platform, which is being integrated into an increasing number of clinics. AI is sometimes highlighted as a potential threat to software companies in medical technology, but in RaySearch's case, the development can rather become a strengthening of their offering. Radiation therapy requires complex planning, large amounts of clinical data, and deep integration into hospital systems. Here, RaySearch has already built up a comprehensive platform and long experience in the field, which means that AI is likely to become a tool that improves and automates parts of the process rather than something that replaces the company's solutions. As more hospitals digitize their treatment workflows and at the same time begin to integrate more advanced analysis and automation, RaySearch can therefore gain an even more important role in the infrastructure surrounding modern cancer treatment. What do you think?
- ·30.3.P/E for the current year is expected to land at 21 according to market data. The reports are better than expected. No threats from competitors, instead Philips is shutting down in 2027, so free market shares are available to take. Board members are buying heavily. The company continues to grow well and AI is no threat in the near term. Why isn't the share price rising when it has been halved? Well, it's probably the short sellers who are slandering the company just like they do with Bonex. The Financial Supervisory Authority seems to be sleeping its Sleeping Beauty sleep instead of locking up crooks who earn millions from stock manipulation through defamation. The market is out of play again. Nothing is happening...
- ·24.2.I don't understand how software will be outcompeted by AI… to me, it sounds like saying that a chef DOES NOT need their kitchen and their ingredients to be able to cook food. Does anyone agree with me?·5.3.They have used machine learning for the last ten years, nowadays AI
- ·16.2.PE 27 at an all-time low. EBIT at an all-time high. Dividend raised by 33% Record revenue. I find it hard to see AI as a threat. Who takes medical responsibility for malpractice?·18.2.Bought this stock at the same price level as now in 2007 and sold the last ones in 2015 for approx. 75 kr. Felt good then after having bounced at 10 kr when the financial crisis characterized life on the stock market. Now ended up back on the radar via a thread about another medtech company (Dynavox). Time to delve into Raysearch anno 2026 and going forward. Find it extremely difficult to see that AI should be a threat, rather the opposite. There are reports showing that Swedish radiation therapy has fallen behind our Nordic neighbours. One of the reasons is that there is a shortage of oncologists in radiation. AI can relieve these so that the quality of care can be maintained. Relieve, therefore, not replace. It is a low cost in this context to invest in a technology that frees up personnel resources. So as for AI, I am not worried. Other parts I will try to delve into.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 57 | - | - | ||
| 43 | - | - | ||
| 10 | - | - | ||
| 40 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 8.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
2025 Q4 -tulosraportti
57 päivää sitten
‧47 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 8.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
4,00 SEK/osake
Irtoamispäivä 8.5.
1,55%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuRaySearch is, in my opinion, an extremely interesting company in medical technology right now. For many years, the company has built up a strong position in advanced software for radiation therapy, where their systems are used by hospitals worldwide to plan and optimize cancer treatments. What makes the case particularly exciting is the combination of a high technological level, strong market position, and a structurally growth-driven market. The demand for more advanced and individualized radiation therapy continues to increase globally, and RaySearch is well positioned with its software platform, which is being integrated into an increasing number of clinics. AI is sometimes highlighted as a potential threat to software companies in medical technology, but in RaySearch's case, the development can rather become a strengthening of their offering. Radiation therapy requires complex planning, large amounts of clinical data, and deep integration into hospital systems. Here, RaySearch has already built up a comprehensive platform and long experience in the field, which means that AI is likely to become a tool that improves and automates parts of the process rather than something that replaces the company's solutions. As more hospitals digitize their treatment workflows and at the same time begin to integrate more advanced analysis and automation, RaySearch can therefore gain an even more important role in the infrastructure surrounding modern cancer treatment. What do you think?
- ·30.3.P/E for the current year is expected to land at 21 according to market data. The reports are better than expected. No threats from competitors, instead Philips is shutting down in 2027, so free market shares are available to take. Board members are buying heavily. The company continues to grow well and AI is no threat in the near term. Why isn't the share price rising when it has been halved? Well, it's probably the short sellers who are slandering the company just like they do with Bonex. The Financial Supervisory Authority seems to be sleeping its Sleeping Beauty sleep instead of locking up crooks who earn millions from stock manipulation through defamation. The market is out of play again. Nothing is happening...
- ·24.2.I don't understand how software will be outcompeted by AI… to me, it sounds like saying that a chef DOES NOT need their kitchen and their ingredients to be able to cook food. Does anyone agree with me?·5.3.They have used machine learning for the last ten years, nowadays AI
- ·16.2.PE 27 at an all-time low. EBIT at an all-time high. Dividend raised by 33% Record revenue. I find it hard to see AI as a threat. Who takes medical responsibility for malpractice?·18.2.Bought this stock at the same price level as now in 2007 and sold the last ones in 2015 for approx. 75 kr. Felt good then after having bounced at 10 kr when the financial crisis characterized life on the stock market. Now ended up back on the radar via a thread about another medtech company (Dynavox). Time to delve into Raysearch anno 2026 and going forward. Find it extremely difficult to see that AI should be a threat, rather the opposite. There are reports showing that Swedish radiation therapy has fallen behind our Nordic neighbours. One of the reasons is that there is a shortage of oncologists in radiation. AI can relieve these so that the quality of care can be maintained. Relieve, therefore, not replace. It is a low cost in this context to invest in a technology that frees up personnel resources. So as for AI, I am not worried. Other parts I will try to delve into.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 57 | - | - | ||
| 43 | - | - | ||
| 10 | - | - | ||
| 40 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 329 | 68 329 | 0 | 0 |